Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 0.48% | 166.09 | 0.7% | $1108.87m | |
| PFE | Pfizer Inc. | -0.72% | 49.75 | 0.9% | $939.86m | |
| ABBV | AbbVie, Inc. | -0.22% | 142.29 | 1.9% | $831.12m | |
| MRK | Merck & Co., Inc. | -0.47% | 90.59 | 0.7% | $806.25m | |
| LLY | Eli Lilly & Co. | 1.90% | 313.93 | 1.1% | $798.53m | |
| BMY | Bristol-Myers Squibb Co. | -1.36% | 74.54 | 1.0% | $648.45m | |
| SIGA | SIGA Technologies, Inc. | 5.66% | 26.15 | 0.0% | $514.56m | |
| AZN | AstraZeneca Plc | 0.26% | 66.81 | 1.0% | $373.58m | |
| GBT | Global Blood Therapeutics, Inc. | 0.43% | 67.04 | 5.6% | $334.64m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | -1.21% | 231.01 | 8.2% | $285.62m | |
| GSK | GSK Plc | -3.08% | 34.92 | 0.3% | $275.20m | |
| HZNP | Horizon Therapeutics Plc | -3.81% | 64.90 | 5.4% | $222.52m | |
| KRTX | Karuna Therapeutics, Inc. | -1.34% | 273.71 | 0.0% | $217.12m | |
| CCXI | ChemoCentryx, Inc. | 0.18% | 50.81 | 2.9% | $205.42m | |
| RGEN | Repligen Corp. | 1.74% | 255.73 | 6.7% | $190.66m |
Company Profile
Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.